MedTrace Logo

Cell-free DNA in Hereditary And High-Risk Malignancies 1

NCT04261972 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1416

Last updated 2026-01-14

No results posted yet for this study

Summary

The goal of this study is to develop an effective, sensitive blood test that can detect early tumours in patients with known or suspected hereditary cancer syndromes (HCS). If this new blood test is accurate, it could be used to screen patients for cancer and allow for earlier cancer detection. The study will also use questionnaires and interviews to understand how patients feel about incorporating these tests into routine medical care, and the perceptions of the medical value of test results.

Conditions

  • Hereditary Cancer Syndrome

Interventions

GENETIC

Next generation sequencing (NGS)

NGS

Sponsors & Collaborators

  • IWK Health Centre

    collaborator OTHER

  • British Columbia Cancer Agency

    collaborator OTHER

  • Sinai Health System

    collaborator OTHER

  • Women's College Hospital

    collaborator OTHER

  • Jewish General Hospital

    collaborator OTHER

  • Eastern Health

    collaborator OTHER

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Raymond Kim, MD · Princess Margaret Cancer Centre

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2024-12-31
Completion
2026-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04261972 on ClinicalTrials.gov